Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02512692 · ClinicalTrials.gov registry record · NA
Gemcitabine-Cisplatin-90Y TARE for Unresectable Intrahepatic Cholangiocarcinoma
A NA study, sponsored by Medical University of South Carolina.
- Terminated
- Registry status
- NA
- Development phase
- 6
- Enrollment target
NCT02512692: Clinical Trial NA study, sponsored by Medical University of South Carolina.
NCT02512692 is a NA study that was terminated before completion, run by Medical University of South Carolina. The registered enrollment target is 6 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02512692, a NA study, was terminated before completion, sponsored by Medical University of South Carolina.
- TERMINATED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and maximum tolerated dose (MTD) of 90 Y TARE (Y90) in combination with gemcitabine and cisplatin in patients with unresectable intrahepatic cholangiocarcinoma (ICC).
Primary Outcome
A continual reassessment method (CRM) design will be used to confirm the Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 in regards to 90Y TARE.
Interventions
- DRUG Cisplatin
- DRUG Gemcitabine
- DEVICE SIR-Spheres microspheres (Yttrium-90 Microspheres)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2015-07-21 |
| Est. Completion | 2021-03-19 |
| Phase | NA |
Why NCT02512692 stopped before completion
NCT02512692 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 3 interventions - of which Cisplatin is the first listed.
NCT02512692 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02512692 about?
NCT02512692 is a clinical study titled "Gemcitabine-Cisplatin-90Y TARE for Unresectable Intrahepatic Cholangiocarcinoma". The purpose of this study is to determine the safety and maximum tolerated dose (MTD) of 90 Y TARE (Y90) in combination with gemcitabine and cisplatin in patients with unresectable intrahepatic cholangiocarcinoma (ICC).
What is the current status of trial NCT02512692?
This trial is currently terminated. It is a NA study. The enrollment target is 6 participants. The study started on 2015-07-21. Estimated completion is 2021-03-19.
What interventions are being tested in trial NCT02512692?
The interventions under investigation include: Cisplatin (DRUG), Gemcitabine (DRUG), SIR-Spheres microspheres (Yttrium-90 Microspheres) (DEVICE).
Who is sponsoring clinical trial NCT02512692?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02512692's enrollment target sits among peer trials
6 1983rd of 2000 higher than 13 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI